Anatolian Current Medical Journal (ACMJ) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

EndNote Style
Original Article
Using hormonotherapy in breast cancer and its relationship with metabolic syndrome
Aims: This study aims to investigate whether the use of hormonotherapy pharmaceuticals causes metabolic syndrome-like symptoms in patients diagnosed with breast cancer and to compare the long-term effects of the drugs.
Methods: This retrospective file analysis was conducted on breast cancer patients who presented to the Radiation Oncology clinic between January 2019 and April 2022. Files of 75 patients diagnosed with breast cancer, postmenopausal, and without any previous chronic diseases such as diabetes or hypertension were included in the study. Patients who were started on medications with different active ingredients (tamoxifen citrate, letrozole or anastrazole) in the adjuvant period were examined in 3 groups. Waist circumference thickness, body weight, blood pressure, and blood biochemical tests (blood glucose, lipid levels) were measured before and 6 months after the start of the drugs, and the values were compared retrospectively.
Results: Of the 75 patients included in the study, the average age of patients using tamoxifen was 59.6; The average age of patients using letrozole was 59.12 years and the average age of patients using anastrozole was 63.56 years. There was an increase in fasting blood sugar (p:0.014) and waist circumference (p:0.009) in the tamoxifen group. There was an increase in fasting blood sugar, weight, waist circumference, blood pressure and lipid levels in the letrozole and anastrazole arms (p<0.0001 for all). Furthermore, comorbidities such as diabetes mellitus and hypertension that developed after using drugs were ascertained.
Conclusion: We think that there is a significant association between hormonotherapy medicines used in breast cancer and metabolic syndrome. While we found increases in blood lipids, FBG, body weight, and waist circumference in most of the patients, we observed that these increases were significantly higher in the groups using aromatase inhibitors. These patients should be examined in detail before starting hormone therapy. Diet, active lifestyle, and sports should be recommended.

1. Jacques F, Isabelle S, Rajesh D, et al. Cancer incidence andmortality worldwide: sources, methods and major patterns inGLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386.
2. Wani B, Aziz SA, Ganaie MA, Mir MH. Metabolic syndrome andbreast cancer risk. Indian J Med Paediatr Oncol. 2017;38(04):434-439.
3. Balkau B, Valensi P, Eschwege E, Slama G. A review of themetabolic syndrome. Diabetes Metabolism. 2007;33(6):405-413.
4. Ray A, Fıcek M. Immunomodulatory effects of antiestrogenicdrugs. Acta Pharm. 2012;62(2):141-155.
5. Kang C, LeRoith D, Gallagher EJ. Diabetes, obesity, and breastcancer. Endocrinol. 2018;159(11):3801-3812. doi: 10.1210/en.2018-00574
6. Wright N, Akinyemiju T, Subhedar P, Rida P, Aneja R. Targetingrisk factors for reducing the racially disparate burden in breastcancer. Front Biosci. 2019;11(1):136-160. doi: 10.2741/s531
7. Ming Xie, Yan Zhong, Yide Yang, Fang Shen, Yue Nie. Extendedadjuvant endocrine therapy for women with hormonereceptor-positive early breast cancer: a meta-analysis with trialsequential analysis of randomized controlled trials. Front Oncol.2022;12:1039320. doi:10.3389/fonc.2022.1039320
8. Battisti NML, Smith IE. Preventing late recurrence in hormonereceptor-positive early breast cancer: a review. Eur J Cancer.2022;172:53-64. doi: 10.1016/j.ejca.2022.05.028
9. Zackariah C, James K, Janne B, Robert W, Melissa B. Extendedduration of adjuvant aromatase inhibitor in breast cancer: ameta-analysis of randomized controlled trials. Gland Surg.2018;7(5):449-457. doi: 10.21037/gs.2018.08.03
10. Pasanisi P, Berrino F, De Petris M, Elisabetta V, Antonio M,Salvatore P. Metabolic syndrome as a prognostic factor for breastcancer recurrences. Int J Cancer. 2006;119(1):236-238.
11. Vona DL, Howard MM, Rose DP. Adiposity, type 2 diabetesand the metabolic syndrome in breast cancer. Obes Rev.2007;8(5):395-408.
12. Agnoli C, Berrino F, Abagnato CA, et al. Metabolic syndrome andpostmenopausal breast cancer in the ORDET cohort: a nestedcase-conrtol study. Nutr Metab Cardiovasc Dis. 2010;20(1):41-47.
13. Kuhl H. Breast cancer risk in the WHI study: the problem ofobesity. Maturitas. 2005;51(1):83-97.
14. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolicsyndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402-2411.
15. Mendonca FM, de Sousa FR, Barbosa AL, et al. Metabolicsyndrome and risk of cancer: which link? Metabolism.2015;64(2):182-189. doi:10.1016/j.metabol.2014.10.008
16. Metabolik Sendrom Araştırma Grubu. METSAR sonu&ccedil;ları.XX.Ulusal Kardiyoloji Kongresi. Antalya, 2004.
17. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis andmanagement of the metabolic syndrome: an American HeartAssociation/National Heart, Lung, and Blood Institute ScientificStatement. Circulation. 2005;112(17):2735-2752.
18. Sinagra D, Amato C, Scarpilta AM, et al. Metabolic syndromeand breast cancer risk. Natl Cancer Inst. 2004;96:1152-1160.
19. Johansson H, Gandini S, Guerrieri GA, et al. Effect of fenretinideand low dose tamoxifen on insulin sensitivity in premenopausalwomen at high ris for breast cancer. Cancer Res. 2008;68(22):9512-9518.
20. Bordeleau L, Lipscombe L, Lubinski J, et al. Diabetes and breastcancer among women with BRCA1 and BRCA2 mutations.Cancer. 2011;17:1812-1818.
21. Yazıcı G, Sayın M. Role of aromatase inhibitors in glucoseintolerance of obese men. Med Hypotheses. 2008;71(4):612-613.doi:10.1016/j.mehy.2008.05.012
22. La Merrill M, Baston DS, Denison MS. Mouse breast cancermodel-dependent changes in metabolic syndrome-associatedphenotypes caused by maternal dioxin exposure and dietary fat.Am J Physiol Endocrinol Metab. 2009;296(1):203-210.
23. Furberg AS, Veierod MB, Wilsgaard T, et al. Serum highdensitylipoprotein, cholesterol, metabolic profile, and breast cancer risk.Natl Cancer Inst. 2004;96(15):1152-1160.
24. Sarıcı F, Sunar V, Aksoy S. The frequency and determinants ofmetabolic syndrome in operated patients with stage I-III breastcancer. Int J Hematol Oncol. 2022;33(3):001-010.
25. Maiti B, Kundranda MN, Spiro TP, Daw HA. The association ofmetabolic syndrome with triple-negative breast cancer. BreastCancer Res Treat. 2010;121(2):479-483.
26. Kozan &Ouml;, Oguz A, Abaci A, et al. Prevalence of the metabolicsyndrome among Turkish adults. Eur J Clin Nutr. 2007;61(4):548-553.
27. Lippman SM, Hong WK. Cancer Prevention, Cecil MedicineInternational Edition. Ed. Goldman L, Ausiello D. Philadelphia,Saunders Elsevier. 2008;1367-1370.
28. Capasso I, Esposito E, Pentimalli F, Anna C, Maurizio M, Maria G.Metabolic syndrome affects breast cancer risk in postmenopausalwomen. National Cancer Institude of Naples experience. CancerBiol Ther. 2010;10(12):1240-1243.
29. Liu LN, Miaskowski C, Wang JS, Shin-Cheh C, Mei-Ling C.Accuracy of body mass index to determine obesity in womenwith breast cancer: an observational study of TaiWanese sample.Int J Nurs Stud. 2010;47(8):994-1000.
Volume 6, Issue 1, 2024
Page : 80-86